GoKawiilPharma firms continue psychedelic drug research despite trial setbacks
Several pharmaceutical companies are continuing to invest in psychedelic compounds as potential treatments for mental-health conditions, even after some clinical trials have produced disappointing results. Separately, researchers are expanding longevity science beyond humans, testing repurposed drugs and new gene therapies to extend lifespan and treat age-related conditions in pets such as dogs and cats.
GoKawiil's interpretation of the reporting above, not reported fact.
Continued investment in psychedelics suggests drugmakers still see a viable market for new mental-health treatments despite scientific and regulatory hurdles, though the setbacks mentioned could signal unresolved safety or efficacy questions. The extension of longevity research to animals reflects how human-focused biotech advances are increasingly being adapted for commercial and scientific use in veterinary medicine.
- Pharma companies remain committed to psychedelic drug development despite trial setbacks.
- Longevity researchers are now applying human-lifespan science to pets, including gene therapy trials.
- Animal-specific treatments are being developed for conditions like muscle wasting and heart disease.
Source: nature.com — Smith, 2026-10-27
Published there as: “Daily briefing: The future of psychedelics”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.